In the CodeBreak 200 and KRYSTAL-12 phase III trial, the mPFS in patients with previously treated advanced/metastatic NSCLC harboring a KRAS G12C mutation with sotorasib and adagrasib were 5.6 months and 5.49 months, respectively, indicating limited efficacy as monotherapies [15, 16]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.